Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

MBCProject_0946_T1_RNA

— · C

4023b49d-04fa-53db-a071-52ac5ba7c375

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
C
subtype
C

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • MYC_TARGETS_V1+0.420
  • OXIDATIVE_PHOSPHORYLATION+0.400
  • ANDROGEN_RESPONSE+0.320
  • PANCREAS_BETA_CELLS+0.300
  • ESTROGEN_RESPONSE_LATE+0.270
  • PROTEIN_SECRETION+0.270
  • TGF_BETA_SIGNALING+0.270
  • APOPTOSIS+0.240
  • ESTROGEN_RESPONSE_EARLY+0.240
  • G2M_CHECKPOINT+0.240

Top 10 suppressed

  • INTERFERON_ALPHA_RESPONSE-0.410
  • INTERFERON_GAMMA_RESPONSE-0.360
  • ALLOGRAFT_REJECTION-0.270
  • INFLAMMATORY_RESPONSE-0.250
  • MYOGENESIS-0.220
  • WNT_BETA_CATENIN_SIGNALING-0.210
  • IL6_JAK_STAT3_SIGNALING-0.190
  • HEDGEHOG_SIGNALING-0.180
  • COMPLEMENT-0.160
  • KRAS_SIGNALING_DN-0.160

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR25617890
breast-umap@18
—B0.797
2SRR8518238
breast-umap@18
—C0.779
3TCGA-A8-A09T-01A-11R-A00Z-07
breast-umap@18
—B0.777
4TCGA-A2-A0ER-01A-21R-A034-07
breast-umap@18
—B0.771
5SRR12202419
bladder-landscape@3
——0.768
6SRR1797299
lung-landscapes@6
—cohortSC0.765
7TCGA-BH-A0H9-01A-11R-A056-07
breast-umap@18
—B0.764
8MNG775
mng-umap@100
——0.758
9MBCProject_5953_T1_RNA
breast-umap@18
—B0.749
10SRR12696752
melanoma-umap@29
——0.747

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 27 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
MYC_TARGETS_V10.420Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.400Remibrutinib— uncovered
ANDROGEN_RESPONSE0.320Inavolisib— uncovered
PANCREAS_BETA_CELLS0.300Cobimetinib— uncovered
ESTROGEN_RESPONSE_LATE0.270Idelalisib— uncovered
PROTEIN_SECRETION0.270Remibrutinib— uncovered
TGF_BETA_SIGNALING0.270Inavolisib— uncovered
APOPTOSIS0.240Idelalisib— uncovered
ESTROGEN_RESPONSE_EARLY0.240Inavolisib— uncovered
G2M_CHECKPOINT0.240Inavolisib— uncovered
MTORC1_SIGNALING0.230Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.230Idelalisib— uncovered
FATTY_ACID_METABOLISM0.220Inavolisib— uncovered
E2F_TARGETS0.210Inavolisib— uncovered
ADIPOGENESIS0.200Inavolisib— uncovered
SPERMATOGENESIS0.200Inavolisib— uncovered
UV_RESPONSE_DN0.140Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.130Inavolisib— uncovered
DNA_REPAIR0.080Idelalisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.080Inavolisib— uncovered